Retatrutide
Retatrutide is an advanced triple-agonist peptide currently under investigation for its potential to revolutionize metabolic health. It activates GLP-1, GIP, and glucagon receptors, providing a multi-pronged approach to weight loss, appetite regulation, and energy expenditure. Early research suggests it could achieve greater fat loss than current GLP-1 therapies while improving cardiovascular and metabolic markers.Its triple-receptor activity makes it one of the most promising new peptides for obesity management and overall metabolic optimization.
Product Highlights
Dosing Instructions
Reconstitute with bacteriostatic water as directed. Administer subcutaneously in the abdomen or thigh once weekly. Begin with a conservative dose and adjust only under appropriate guidance.
Compound Information
Primary Use: Investigational peptide for obesity and metabolic disease management.
Class: Triple agonist (GLP-1, GIP, and glucagon receptors).
Molecular Weight: ~4,800 Da.
Formula: Large peptide sequence; empirical formula varies by salt form.
Mechanism: Stimulates GLP-1 and GIP receptors to enhance insulin secretion and satiety, while glucagon receptor activity increases energy expenditure.
Administration: Subcutaneous injection, typically once weekly in trials.
Half-Life: ~6 days.
Note: All peptide products are for research purposes only. Information provided is educational and not a substitute for medical advice.
Reviews
There are no reviews yet.